0001562180-21-001708.txt : 20210301
0001562180-21-001708.hdr.sgml : 20210301
20210301200516
ACCESSION NUMBER: 0001562180-21-001708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kalb Michael Wayne
CENTRAL INDEX KEY: 0001678248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21392
FILM NUMBER: 21700637
MAIL ADDRESS:
STREET 1: 24 LUCILLE LANE
CITY: DIX HILLS
STATE: NY
ZIP: 11746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMARIN CORP PLC\UK
CENTRAL INDEX KEY: 0000897448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C
STREET 2: 77 SIR JOHN ROGERSON'S QUAY
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 353 1 6699 020
MAIL ADDRESS:
STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C
STREET 2: 77 SIR JOHN ROGERSON'S QUAY
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC
DATE OF NAME CHANGE: 20000201
FORMER COMPANY:
FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC
DATE OF NAME CHANGE: 19930322
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-02-25
false
0000897448
AMARIN CORP PLC\UK
AMRN
0001678248
Kalb Michael Wayne
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22
BRIDGEWATER
NJ
08807
false
true
false
false
SVP and CFO
Ordinary Shares
2021-02-25
4
M
false
88614.00
A
218924.00
D
Ordinary Shares
2021-02-25
4
F
false
43395.00
7.30
D
175529.00
D
Ordinary Shares
2021-02-26
4
M
false
1528.00
A
177057.00
D
Ordinary Shares
2021-02-26
4
M
false
1528.00
A
178585.00
D
Ordinary Shares
2021-02-26
4
M
false
3056.00
A
181641.00
D
Ordinary Shares
2021-02-26
4
F
false
2995.00
6.74
D
178646.00
D
Ordinary Shares
2021-02-26
4
M
false
16334.00
A
194980.00
D
Ordinary Shares
2021-02-26
4
F
false
8060.00
6.74
D
186920.00
D
Restricted Stock Units
0.00
2021-02-25
4
M
false
88614.00
0.00
D
Ordinary Shares
88614.00
21386.00
D
Restricted Stock Units
0.00
2021-02-26
4
M
false
1528.00
0.00
D
Ordinary Shares
1528.00
9165.00
D
Restricted Stock Units
0.00
2021-02-26
4
M
false
1528.00
0.00
D
Ordinary Shares
1528.00
9165.00
D
Restricted Stock Units
0.00
2021-02-26
4
M
false
3056.00
0.00
D
Ordinary Shares
3056.00
18330.00
D
Restricted Stock Units
0.00
2021-02-26
4
M
false
16334.00
0.00
D
Ordinary Shares
16334.00
32666.00
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
As previously reported, on May 15 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs consist of 3 tranches representing 25%, 25% and 50% of the total award. Each tranche vests ratably over 36 months beginning Sept. 30 2018 subject to achievement of certain prespecified performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. On Feb. 25 2021, pursuant to reporting of audited net total revenue for 2020 exceeding $500 million, the performance criteria related to the 50% tranche was deemed achieved, resulting in the vesting of 88,614 RSUs (29 of 36 months' worth). The remaining RSUs in this tranche will continue to vest over 7 monthly installments, the first of which vested Feb. 26 2021. The performance criteria related to both 25% tranches were previously deemed achieved (see Footnote 5).
Not applicable.
Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 220,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021.
On March 2, 2020, the Reporting Person was granted 49,000 RSUs under the Plan. These RSUs vest in three equal installments on each of February 28, 2021, February 28, 2022 and February 28, 2023. The first vesting event occurred on February 26, 2021.
Please see the section titled "Remarks" below for additional information.
Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 1,280,579 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs outstanding under the Issuer's stock incentive plans, including but not limited to certain performance-based RSUs that are earned only if certain pre-defined operational milestones are achieved and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.
/s/ Joseph T. Kennedy, by power of attorney
2021-03-01